It was reported yesterday that Hansoh Pharmaceutical Group Company, a biopharmaceutical company in China, has collaborated with Atomwise, a company focused on artificial intelligence for drug discovery.

The collaboration is aimed at designing and discovering potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.

Scientific teams from both firms will work together on the program in order to increase success and speed up drug discovery and clinical development. Hansoh Pharma will contribute its capabilities in biological assays and medicinal chemistry, and lead subsequent preclinical and clinical development activities.

According to the terms of the collaboration, Atomwise will receive undisclosed technology access fees, option exercise fees, royalties, and income based on sublicensing or sale of assets created under the partnership.